SCHEMBL25848350

SCHEMBL25848350

CCc1cc2nc(C(C)C)nn2cn1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13086436 0.78
SCHEMBL25848348 0.71 NAMPT (0.35) NAMPT
SCHEMBL20322349 0.67 TGFBR1 (0.33)
SCHEMBL15935318 0.67 NAMPT (0.31) NAMPT
SCHEMBL12091356 0.66 NAMPT (0.46) NAMPT
SCHEMBL798669 0.65 AHR (0.33) NAMPT
SCHEMBL22681225 0.64 ESR1 (0.40)
SCHEMBL18626423 0.63 HAVCR2 (0.39) NAMPT
SCHEMBL9109466 0.63 AHR (0.53) NAMPT
SCHEMBL9108919 0.63 PIK3CG (0.35) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA NAMPT 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.